Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine for Attention in Alzheimer's Disease
NCT01054976Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2006
- Primary completion
- Feb 2009
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
01
Overview
A Phase 4 trial of galantamine in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Oct 2006; status: completed.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01054976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01054976.